Co-amorphous substance of fenerenone and acid, solid dispersion of co-amorphous substance, preparation method of co-amorphous substance and solid dispersion and application of co-amorphous substance and solid dispersion

By combining the monolenelone with the acid to form a co-amorphous substance and combining it with the excipient, the low solubility and instability of the monolenelone is solved, and a solid dispersion with high solubility and stability is achieved, improving the The bioavailability and storage stability of the drug are achieved.

CN118908956APending Publication Date: 2024-11-08SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310509322.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The poor solubility of crystal form I of the non-nelinone leads to low oral bioavailability and relatively poor stability of amorphous, with risks of transcrystallization and degradation, making it difficult to meet the strict requirements of drug solid preparations.

Method used

Combining the monolenelone with a pharmaceutically acceptable acid to form a co-amorphous substance and dispers it in the excipient, solubility and stability are improved by solid dispersion technology, and X-ray powder diffraction pattern shows the lack of crystallinity , melting method, hot melt extrusion method, grinding method or solvent-melting method are used to prepare solid dispersions.

Benefits of technology

The solubility and stability of the perenone are significantly improved, forming a co-amorphous solid dispersion suitable for high solubility and thermodynamic stability for drug preparations, improving the oral bioavailability of the drug and the stability of production and storage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004216746130000011
    Figure BDA0004216746130000011
  • Figure BDA0004216746130000071
    Figure BDA0004216746130000071
  • Figure BDA0004216746130000081
    Figure BDA0004216746130000081
Patent Text Reader

Abstract

The invention discloses a co-amorphous substance formed by fenerenone and acid and a solid dispersion of the co-amorphous substance, and a preparation method and application of the co-amorphous substance of the fenerenone and the acid and the solid dispersion of the co-amorphous substance of the fenerenone and the acid. Compared with a finerenone crystal form I, a finerenone amorphous form and a finerenone solid dispersion, the co-amorphous substance of the finerenone and the acid and the solid dispersion of the co-amorphous substance of the finerenone and the acid, disclosed by the invention, have the advantages that the solubility in water is remarkably improved, and meanwhile, the co-amorphous substance of the finerenone and the acid shows excellent stability under experimental conditions of high temperature, illumination and the like; the pharmaceutical composition meets the basic requirements of use in pharmaceutical preparations, and has a great prospect in development of patent medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug preparation, and in particular relates to a co-amorphous product of finerenone and acid, a solid dispersion formed by the co-amorphous product of finerenone and acid and an excipient, and preparation methods and uses thereof. Background Art

[0002] Finerenone, chemical name is (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, trade name is Kerendia, chemical structure is as follows:

[0003]

[0004] Finerenone is a non-steroidal selective mineralocorticoid receptor antagonist developed by Bayer for the treatment of chronic kidney disease associated with type 2 diabetes. It has been approved for marketing in many countries and regions including the United States, the European Union, Japan, and China, and is gradually becoming an effective new means to further improve the cardiovascular and renal prognosis of patients with diabetes-related chronic kidney disease.

[0005] Finerenone belongs to BCS Class II drugs, and the solubility of active substances is the key to limiting drug absorption. The PCT patent WO2016016287A1 applied by the original research company reported Form I, which is thermodynamically stable and is the medicinal form of finerenone. However, since the drug dissolution process requires the destruction of lattice energy, Form I has poor solubility and low oral bioavailability.

[0006] Patent IN201911048297 applied by Mankind reported amorphous phenarenic acid, isomers, pharmaceutically acceptable salts, and solid dispersions and preparation methods formed by amorphous phenarenic acid and isomers, but no data such as solubility and stability were reported. It can be predicted that compared with crystalline form I, the amorphous phenarenic acid is in a disordered state, with a larger surface free energy, and the particle surface is easily hydrated, which can improve the solubility of poorly soluble drugs, thereby improving the bioavailability of drugs. However, due to its high free energy, the pure amorphous form has the problem of crystal transformation during storage and transportation, and its stability is relatively poor. Using solid dispersion technology to disperse the drug in a polymer excipient, the stability will be improved, but there is still a great risk of crystal transformation and degradation when storing the drug for a long time.

[0007] Therefore, in order to meet the strict requirements of solid pharmaceutical preparations for the form of active substances and expand the forms of raw materials selected for preparation development, the art needs to develop new solid forms containing finerenone. Summary of the invention

[0008] In view of the shortcomings of the existing technology, we have found through extensive research that finerenone and a pharmaceutically acceptable acid can be made into a co-amorphous substance, the solubility of which is significantly improved, and its stability is better than that of finerenone amorphous. Using solid dispersion technology, the co-amorphous substance made of finerenone and acid is dispersed in an excipient, and the solubility of the obtained co-amorphous solid dispersion is also significantly improved, and its stability is also better than that of finerenone amorphous solid dispersion.

[0009] The present invention provides a thermodynamically stable and highly soluble co-amorphous product of phenerenone and acid, a solid dispersion formed by the co-amorphous product and an excipient, and a preparation method and use thereof.

[0010] One of the objects of the present invention is to provide a co-amorphous product of finerenone and acid, wherein the co-amorphous product of finerenone and acid is formed by combining finerenone and a pharmaceutically acceptable acid, wherein the acid is selected from one of formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, benzoic acid, salicylic acid, naphthalene-2-sulfonic acid, p-hydroxybenzoic acid, malic acid, tartaric acid, mandelic acid, citric acid, oxalic acid, malonic acid, succinic acid, adipic acid, fumaric acid, gluconic acid, maleic acid and nicotinic acid; the X-ray powder diffraction pattern of the co-amorphous product of finerenone and acid has diffuse diffraction packets and no sharp diffraction peaks, indicating a lack of crystallinity.

[0011] Another object of the present invention is to provide a method for preparing a co-amorphous product of finerenone and acid, comprising the following steps: dissolving finerenone and acid in a solvent S1, and removing the solvent S1 from the dissolved solution to obtain the co-amorphous product of finerenone and acid.

[0012] Preferably, the solvent S1 is selected from one or more of C1-C4 alcohols, C3-C4 ketones, C2-C3 nitriles, C3-C5 esters, C1 chlorinated hydrocarbons, ethers, alkanes, and water.

[0013] Preferably, the molar ratio of finerenone to acid is selected from 1:0.5 to 1:5, more preferably 1:0.5 to 1:2.

[0014] Preferably, the dissolving temperature is -5 to 50°C, more preferably 10 to 30°C.

[0015] Another object of the present invention is to provide a solid dispersion of a co-amorphous product of finerenone and an acid, wherein the solid dispersion comprises an excipient, wherein the excipient is selected from one of polyacrylic acid resin, polyethylene glycol, hydroxypropyl cellulose and copovidone, and the acid is selected from one of formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, benzoic acid, salicylic acid, naphthalene-2-sulfonic acid, p-hydroxybenzoic acid, malic acid, tartaric acid, mandelic acid, citric acid, oxalic acid, malonic acid, succinic acid, adipic acid, fumaric acid, gluconic acid, maleic acid and nicotinic acid; and the X-ray powder diffraction pattern of the solid dispersion has diffuse diffraction packets without sharp diffraction peaks, indicating a lack of crystallinity.

[0016] Another object of the present invention is to provide a method for preparing a solid dispersion of a co-amorphous product of finerenone and acid, comprising the steps of dissolving the co-amorphous product of finerenone and acid and an excipient in a solvent S2, and then removing the solvent S2 from the dissolved solution to obtain the solid dispersion.

[0017] Preferably, the weight ratio of the co-amorphous product of finerenone and acid to the excipient is selected from 1:0.1 to 1:10, more preferably 1:0.5 to 1:3.

[0018] Preferably, the solvent S2 is one or more of C1-C4 alcohols, more preferably methanol.

[0019] Preferably, the dissolving temperature is -5 to 60°C, more preferably 10 to 30°C.

[0020] Preferably, the method for preparing the solid dispersion of the co-amorphous product of finerenone and acid further comprises preparing the solid dispersion by melting, hot melt extrusion, grinding or solvent-melting the co-amorphous product of finerenone and acid and an excipient.

[0021] Another object of the present invention is to provide use of a co-amorphous product of finerenone and an acid, and a solid dispersion formed by a co-amorphous product of finerenone and an acid and an excipient in the preparation of a medicament for treating and / or preventing diabetic nephropathy, hyperaldosteronism, hypertension, sequelae of chronic heart failure, myocardial infarction, liver cirrhosis, renal failure and stroke.

[0022] The co-amorphous product of finerenone and acid, and the solid dispersion formed by the co-amorphous product of finerenone and acid and an excipient of the present invention have the following beneficial effects:

[0023] 1) Co-amorphous substances are co-amorphous substances formed by the interaction between drugs and small molecule compounds (such as organic acids). It is a single-phase amorphous binary or more binary system. Co-amorphous drugs can effectively improve the solubility of drugs and greatly improve the stability of drugs. For poorly soluble drugs such as finerenone, compared with simple crystalline and amorphous forms, the co-amorphous drugs of finerenone have good development advantages. Through solubility experiments in water, the solubility of the co-amorphous substances of finerenone and acid, the solid dispersions formed by the co-amorphous substances of finerenone and acid and excipients of the present invention in water are significantly better than those of finerenone crystalline form I, finerenone amorphous and finerenone solid dispersions. This property makes the co-amorphous substances of finerenone and acid, the solid dispersions formed by the co-amorphous substances of finerenone and acid and excipients of the present invention more suitable for preparing solid preparations, improving the solubility of drugs in the body, thereby improving oral bioavailability.

[0024] 2) Through stability test investigation, the co-amorphous product of finerenone and acid, and the solid dispersion formed by the co-amorphous product of finerenone and acid and excipients of the present invention showed excellent stability under the solid-state stability test conditions, indicating that the co-amorphous product of finerenone and acid, and the solid dispersion formed by the co-amorphous product of finerenone and acid and excipients of the present invention are suitable for the production and storage of drugs, and have great potential for development into pharmaceutical preparations.

[0025] Description of the Invention

[0026] The term "amorphous" in the present invention can be replaced by "amorphous form". "Amorphous" or "amorphous form" refers to a substance in which the particles (molecules, atoms or ions) of the substance are arranged in a three-dimensional space without periodicity, and is characterized by a diffuse X-ray powder diffraction pattern without sharp peaks.

[0027] In the present invention, "solid dispersion of co-amorphous product of finerenone and acid" and "solid dispersion formed by co-amorphous product of finerenone and acid and excipient" are interchangeable, and are formed by mixing and dissolving the co-amorphous product of finerenone and acid with excipients (the excipients in the present invention are specifically polymers such as polyacrylic acid resin, polyethylene glycol, hydroxypropyl cellulose or copovidone) in a dissolving solvent and removing the solvent in a conventional manner in the art, such as spray drying, rotary evaporation, evaporation, freeze drying, filtration, etc. It should be understood that the solid dispersion of co-amorphous product of finerenone and acid in the present invention can also be prepared by methods known to those skilled in the art, including but not limited to melting method, hot melt extrusion method, grinding method or solvent-melting method. The melting method refers to mixing the co-amorphous substance of finerenone and acid with the excipient, heating until it melts, and rapidly cooling the melt into a solid under vigorous stirring, or pouring the melt into a cooled container to form a thin layer. Cold air can be blown under the container or ice can be used for quenching to rapidly cool and solidify it to form a low eutectic solid dispersion. The hot melt extrusion method refers to heating and melting the co-amorphous substance of finerenone and acid with the aforementioned excipients, so that the co-amorphous substance of finerenone and acid is highly dispersed in the excipient, and then extruding under appropriate conditions to obtain a solid dispersion with uniform appearance and density. The grinding method refers to mixing the co-amorphous substance of finerenone and acid with the aforementioned excipients and grinding them for a certain period of time to form a solid dispersion. The solvent-melt method refers to dissolving the co-amorphous product of finerenone and acid in a small amount of organic solvent (C1-C4 alcohol), then directly adding the solution to the melted excipient and mixing evenly, evaporating the solvent, and cooling and solidifying according to the melt method to obtain a solid dispersion.

[0028] In the present invention, specific examples of the "C1-C4 alcohol" include methanol, ethanol, n-propanol, isopropanol, 1-butanol, and 2-butanol.

[0029] In the present invention, specific examples of the "C3-C4 ketone" include acetone and butanone.

[0030] In the present invention, specific examples of the "C2-C3 nitrile" include acetonitrile and propionitrile.

[0031] In the present invention, specific examples of the "C3-C5 esters" include ethyl formate, propyl formate, isopropyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, methyl propionate, ethyl propionate, methyl isopropionate, and ethyl isopropionate.

[0032] In the present invention, specific examples of the "C1 chlorinated hydrocarbon" include dichloromethane and chloroform.

[0033] In the present invention, specific examples of the "ether" include diethyl ether, isopropyl ether, methyl tert-butyl ether, tetrahydrofuran, and dioxane.

[0034] In the present invention, specific examples of the "alkanes" include n-hexane, n-heptane, and petroleum ether.

[0035] In the present invention, the "removal of solvent" can be accomplished by conventional techniques in the art, such as filtration, centrifugation, rotary evaporation, evaporation, freeze drying, spray drying, etc.

[0036] V / V: represents volume ratio. Unless otherwise specified, the component ratios of the mixed solvents in the embodiments of the present invention are all volume ratios.

[0037] The phenerenone used for preparing the co-amorphous compound in the present invention is prepared according to the teaching of Example 1 of patent CN108473488A.

[0038] The polyacrylic acid resin of the present invention is polyacrylic acid resin III purchased from Anhui Shanhe Pharmaceutical Excipients Co., Ltd. and polyacrylic acid resin IV purchased from Lianyungang Wantai Pharmaceutical Excipients Technology Co., Ltd. These two polyacrylic acid resins can be used interchangeably in the specific embodiments of the present invention; the polyethylene glycol of the present invention is polyethylene glycol 6000 purchased from Jiangxi Alpha High-Tech Pharmaceutical Co., Ltd.; the hydroxypropyl cellulose of the present invention is hydroxypropyl cellulose NHD-1231 purchased from Japan Soda Co., Ltd.; the copolyvidone of the present invention is copolyvidone VA64 purchased from Chongqing Steckreidenmeier Materials Technology Co., Ltd. It should be noted that the above description of the source and specifications or models of the polymers is only for illustration, not for limitation, so the above polymers are referred to by common names such as polyacrylic acid resin, polyethylene glycol, hydroxypropyl cellulose, and copolyvidone in the embodiments of the present invention without models or specifications.

[0039] "eq" in the examples of the present invention means equivalent, which is the value obtained by dividing the number of moles of acid (calculated as pure acid) by the number of moles of finerenone.

[0040] Unless otherwise specified, other conventional reagents used in the present invention are commercially available.

[0041] The dissolving temperature in the present invention, unless otherwise specified, refers to room temperature, and the specific temperature of room temperature is 10-30°C. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 It is the XRPD pattern of the co-amorphous product of finerenone and formic acid of the present invention.

[0043] Figure 2 It is the XRPD pattern of the co-amorphous product of finerenone and malic acid of the present invention.

[0044] Figure 3 The XRPD pattern of the co-amorphous product of finerenone and tartaric acid of the present invention is shown in FIG.

[0045] Figure 4It is the XRPD pattern of the co-amorphous product of finerenone and citric acid of the present invention.

[0046] Figure 5 The XRPD pattern of the co-amorphous product of finerenone and oxalic acid of the present invention is shown in FIG.

[0047] Figure 6 The XRPD spectrum of the solid dispersion formed by the co-amorphous product of finerenone and tartaric acid and copovidone of the present invention.

[0048] Figure 7 The XRPD spectrum of the solid dispersion formed by the co-amorphous product of finerenone and oxalic acid and polyacrylic acid resin of the present invention.

[0049] Figure 8 The XRPD spectrum of the solid dispersion formed by the co-amorphous product of finerenone and malic acid and polyethylene glycol of the present invention.

[0050] Fig. 9 The XRPD spectrum of the solid dispersion formed by the co-amorphous product of finerenone and citric acid and hydroxypropyl cellulose of the present invention.

[0051] Fig.10 Among them, 10-1, 10-2, 10-3, and 10-4 represent the XRPD spectra of polyacrylic acid resin, polyethylene glycol, hydroxypropyl cellulose, and copovidone, respectively. DETAILED DESCRIPTION

[0052] The embodiments of the present invention are described in detail below in conjunction with specific examples, but those skilled in the art should understand that the examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.

[0053] The X-ray powder diffraction analysis method used in the present invention is as follows: the instrument is a TDM-10 diffractometer, using Cu-Kα radiation, and the acquisition software is TDXRPD. The instrument is calibrated with the standard product provided with the instrument before use. The detection conditions are as follows: 2θ scanning angle range: 3-40°, step length: 0.02°, speed: 1.0 sec / step. Detection process: under the operating conditions of 40 kV and 20 mA, the sample is tested at room temperature, and the sample to be tested is placed on a non-reflective plate. Unless otherwise specified, the sample is not ground before testing.

[0054] The solubility in the present invention is determined by high performance liquid chromatography (HPLC), and the data is collected from SHIMADZU LC-20AD / Thermo U3000 (UV / DAD). A C18 chromatographic column, 250mm*4.6mm, column temperature 35°C, wavelength 226nm, flow rate 1.0mL / min, injection volume 10μL, running time 5min. Mobile phase A is 10mmol / L ammonium acetate (pH=4.6): acetonitrile=90:10 (V / V), and mobile phase B is acetonitrile. The gradient is A%:B%=50:50.

[0055] The purity of the present invention is determined by high performance liquid chromatography (HPLC), and the data is collected from SHIMADZU LC-20AD / Thermo U3000 (UV / DAD). A C18 chromatographic column, 250mm*4.6mm, column temperature 35°C, wavelength 226nm, flow rate 1.0mL / min, injection volume 10μL, running time 30min. Mobile phase A is 10mmol / L ammonium acetate (pH=4.6): acetonitrile=90:10 (V / V), and mobile phase B is acetonitrile. The gradient is shown in Table 1 below:

[0056] Time min A% B% 0 70 30 15 30 70 20 30 70 21 70 30 30 70 30

[0057] Preparation Example 1: Preparation of Finerenone Crystal Form I

[0058] Finerenone Form I was prepared using the method taught in Example 9 of patent WO2016016287A1.

[0059] Preparation Example 2: Preparation of phenerenone amorphous

[0060] Finerenone amorphous was prepared using the method taught in Example 4 of patent IN201911048297.

[0061] Preparation Example 3: Preparation of fenaredon hydroxypropyl cellulose solid dispersion

[0062] The phenerenone hydroxypropyl cellulose solid dispersion was prepared using the method taught in Example 7 of patent IN201911048297.

[0063] Example 1: Preparation of a co-amorphous product of finerenone and formic acid

[0064] 1.5 g of finerenone was added to 37 ml of methanol, 2 eq of formic acid was added dropwise, and the mixture was stirred to dissolve to obtain a solution. The solvent was removed from the solution by rotary evaporation to obtain a co-amorphous product of finerenone and formic acid.

[0065] XRPD spectrum see Figure 1 .

[0066] Embodiment 2~embodiment 21:

[0067] Referring to the preparation method of Example 1, the following combinations of experimental conditions are used to replace the experimental conditions of Example 1 to prepare the co-amorphous substance of phenerenone and the corresponding acid in Table 2 below:

[0068]

[0069]

[0070] The amount of phenerenone added in the above embodiments is 1.5 g, wherein the volume of dichloromethane in Embodiment 7 is 10 mL, the total volume of dichloromethane and methanol in Embodiment 9 is 20 mL, the volume of dichloromethane in Embodiment 12 is 30 mL, the total volume of methanol and acetonitrile in Embodiment 16 is 22 mL, the total volume of dichloromethane and methanol in Embodiment 17 is 20 mL, the total volume of dichloromethane and ethanol in Embodiment 19 is 24 mL, the total volume of dichloromethane and ethanol in Embodiment 20 is 15 mL, the total volume of ethyl acetate and methanol in Embodiment 21 is 30 mL, and the volume of solvent added in the remaining embodiments is 37 mL.

[0071] The XRPD patterns of the co-amorphous products of finerenone and acid prepared in Examples 10, 11, 13 and 14 are shown in Table 1. Figure 2 , Figure 3 , Figure 4 and Figure 5 The XRPD patterns of the finerenone co-amorphous products prepared in other examples in Table 2 are similar to those described above. Figures 1 to 5 Similarly, both show diffuse diffraction packets without sharp diffraction peaks, indicating a lack of crystallinity. However, due to space limitations, the XRPD spectra of the co-amorphous products of finerenone and acid prepared in other embodiments in Table 2 are no longer listed one by one.

[0072] Example 22: Solid dispersion of amorphous finerenone and tartaric acid and copolyvidone

[0073] Dissolve 0.3 g of amorphous product of finerenone and tartaric acid in 15 ml of methanol, add 0.6 g of copolyvidone, and heat to 60°C to dissolve. After dissolving, remove the solvent by rotary evaporation to obtain the solid dispersion described in the title.

[0074] XRPD spectrum see Figure 6 .

[0075] Example 23: Solid dispersion of a co-amorphous product of finerenone and oxalic acid and polyacrylic acid resin

[0076] 0.3 g of amorphous product of finerenone and oxalic acid was dissolved in 15 ml of methanol, 0.6 g of polyacrylic acid resin was added, and the mixture was heated to 50°C to dissolve. After dissolving, the solvent was removed by rotary evaporation to obtain the solid dispersion described in the title.

[0077] XRPD spectrum see Figure 7 .

[0078] Example 24: Solid dispersion of a co-amorphous product of finerenone and malic acid and polyethylene glycol

[0079] Dissolve 0.3 g of amorphous product of finerenone and malic acid in 15 ml of methanol, add 0.6 g of polyethylene glycol, and heat to 60°C to dissolve. After dissolving, remove the solvent by rotary evaporation to obtain the solid dispersion described in the title.

[0080] XRPD spectrum see Figure 8 .

[0081] Example 25: Solid dispersion of a co-amorphous product of finerenone and citric acid and hydroxypropyl cellulose

[0082] 0.3 g of amorphous product of finerenone and citric acid was dissolved in 15 ml of methanol, 0.6 g of hydroxypropyl cellulose was added, and the mixture was heated to 50° C. to dissolve. After dissolving, the solvent was removed by rotary evaporation to obtain the solid dispersion described in the title.

[0083] XRPD spectrum see Fig. 9 .

[0084] Examples 22 to 25 disclose that co-amorphous substances formed by oxalic acid, acetic acid, malic acid and citric acid of finerenone respectively form solid dispersions with excipients polyacrylate resin, polyethylene glycol, hydroxypropyl cellulose and copovidone. According to the preparation methods disclosed in Examples 22 to 25 and the common properties and XRPD spectra of the obtained solid dispersions, it can be predicted that the other co-amorphous substances disclosed in Examples 1 to 21 of the present invention can form solid dispersions with the above four excipients respectively, and their XRPD spectra can also show similar or identical characteristics to the solid dispersions of Examples 22 to 25.

[0085] Test Example 1: Water Solubility Test

[0086] The sample was ground in a mortar, and the excess sample was put into 10 mL of purified water (pre-placed in a 37°C water bath for constant temperature), and shaken every 10 minutes. When sampling, 3 mL of supernatant was taken, filtered through a 0.22 μm hydrophilic PTFE filter, and the initial 2 mL was discarded. The filtrate was taken for dilution (diluted according to the dissolution condition), and the diluent was acetonitrile. The water solubility of the samples in Table 3 was determined by HPLC. The solubility of each sample is as follows:

[0087] Table 3: Solubility of samples in water

[0088]

[0089]

[0090] The results show that the solubility of the co-amorphous product of finerenone and acid and its solid dispersion in water is significantly better than that of finerenone crystalline form I, finerenone amorphous form and its solid dispersion.

[0091] Test Example 2: Solid-state stability test

[0092] The samples were sealed and placed at high temperature (60°C) for 10 days and exposed to light (25°C, and exposed to cool white fluorescent light and near ultraviolet light at 4500lx±500lx. The total illumination of the light source should not be less than 1.2×106lux·hr, and the energy of the near ultraviolet light should not be less than 200W·hr / m 2 ) and left open for 10 days. The crystal form of the samples before and after the high temperature and light irradiation experiments was determined by X-ray powder diffraction, and the purity of the samples before and after the high temperature and light irradiation experiments was determined by HPLC. The results are shown in Table 4 below:

[0093]

[0094]

[0095] Note: "No change" in Table 4 means that the corresponding samples did not undergo crystal transformation before and after high temperature and light irradiation. "Sharp diffraction peaks appeared" and "Obviously sharp diffraction peaks appeared" mean that there were no sharp diffraction peaks in the XRPD spectrum of the corresponding samples before the experiment, and crystal transformation occurred after the experiment, and sharp diffraction peaks appeared.

[0096] The results of the stability test show that the co-amorphous product of finerenone and acid and its solid dispersion of the present invention have stable crystal form under the conditions of investigation, and the HPLC purity has no significant change. However, the crystal form of amorphous finerenone and its solid dispersion is unstable under high temperature and light conditions, and crystal transformation will occur. Finerenone crystal form I, finerenone amorphous finerenone and its solid dispersion are degraded to varying degrees before and after the light experiment.

Claims

1. A co-amorphous product of finerenone and an acid, characterized in that: The co-amorphous product of finerenone and acid is formed by combining finerenone and a pharmaceutically acceptable acid, wherein the acid is selected from the group consisting of formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, benzoic acid, salicylic acid, naphthalene-2-sulfonic acid, p-hydroxybenzoic acid, malic acid, tartaric acid, mandelic acid, citric acid, oxalic acid, malonic acid, succinic acid, adipic acid, fumaric acid, gluconic acid, maleic acid and nicotinic acid; The X-ray powder diffraction pattern of the co-amorphous product of finerenone and acid shows diffuse diffraction packets without sharp diffraction peaks, indicating a lack of crystallinity.

2. A method for preparing the co-amorphous product of finerenone and acid according to claim 1, characterized in that: The method comprises the following steps: dissolving finerenone and acid in a solvent S1, and removing the solvent S1 from the dissolved solution to obtain a co-amorphous substance of finerenone and acid.

3. The preparation method according to claim 2, characterized in that: The solvent S1 is selected from one or more of C1-C4 alcohols, C3-C4 ketones, C2-C3 nitriles, C3-C5 esters, C1 chlorinated hydrocarbons, ethers, alkanes, and water.

4. The preparation method according to claim 2 or 3, characterized in that: The molar ratio of finerenone to acid is selected from 1:0.5 to 1:5, preferably 1:0.5 to 1:

2.

5. The preparation method according to any one of claims 2 to 4, characterized in that: The dissolving temperature is -5 to 50°C, preferably 10 to 30°C.

6. A solid dispersion comprising the co-amorphous product of finerenone and an acid according to claim 1 or the co-amorphous product of finerenone and an acid prepared according to the preparation method according to any one of claims 2 to 5, wherein the solid dispersion further comprises an excipient, wherein the excipient is selected from one of polyacrylic acid resin, polyethylene glycol, hydroxypropyl cellulose and copovidone; the X-ray powder diffraction pattern of the solid dispersion has diffuse diffraction packets without sharp diffraction peaks, indicating a lack of crystallinity.

7. A method for preparing a solid dispersion according to claim 6, characterized in that: The method comprises the following steps: dissolving the co-amorphous product of finerenone and acid and an excipient in a solvent S2, and then removing the solvent S2 from the dissolved solution to obtain the solid dispersion.

8. The preparation method according to claim 7, characterized in that: The solvent S2 is one or more of C1-C4 alcohols, preferably methanol; the dissolution temperature is -5-60°C, more preferably 10-30°C.

9. Use of the co-amorphous substance according to claim 1 or the solid dispersion according to claim 6 in the preparation of a medicament for treating and / or preventing diabetic nephropathy, hyperaldosteronism, hypertension, sequelae of chronic heart failure, myocardial infarction, cirrhosis, renal failure and stroke.

Citation Information

Cited By

  • New crystal form of fenerenone, preparation method and application

    CN121226372A

  • Felnerenone acetic acid solvate, preparation method and application

    CN121873071A